Abstract |
This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-beta1a in relapsing-remitting multiple sclerosis (RRMS). Patients (n = 180) were randomized (2 : 1) to IFN-beta1a or placebo for 16 weeks; all patients then received IFN-beta1a for 24 weeks. Monthly brain MRI was performed. At week 16, the mean number of combined unique active (CUA) lesions was lower with IFN-beta1a than with placebo (p < 0.001; 69% fewer lesions). The mean cumulative number of CUA lesions was already lower with IFN-beta1a by week 4 (post hoc analysis; p = 0.015). The new formulation of sc IFN-beta1a has rapid beneficial effects on MRI outcomes in RRMS.
|
Authors | Nicola De Stefano, François Curtin, Bettina Stubinski, Gregg Blevins, Jelena Drulovic, Delphine Issard, Penko Shotekov, Claudio Gasperini, IMPROVE Study Investigators |
Journal | Multiple sclerosis (Houndmills, Basingstoke, England)
(Mult Scler)
Vol. 16
Issue 7
Pg. 888-92
(Jul 2010)
ISSN: 1477-0970 [Electronic] England |
PMID | 20200197
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Immunologic Factors
- Interferon-beta
- Interferon beta-1a
|
Topics |
- Brain
(drug effects, pathology)
- Chemistry, Pharmaceutical
- Double-Blind Method
- Europe
- Humans
- Immunologic Factors
(administration & dosage)
- Injections, Subcutaneous
- Interferon beta-1a
- Interferon-beta
(administration & dosage)
- Magnetic Resonance Imaging
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy, pathology)
- Time Factors
- Treatment Outcome
|